Importantly, resistant cancer cells often compensate for MAPK inhibition by activating parallel survival pathways such as PI3K/AKT/mTOR, suggesting that dual inhibition of mTOR and MAPK signaling in combination with L-ASNase could be an effective strategy to prevent resistance. This evidence concerns the gene MTOR and cancer.